Show Summary Details
Page of

Malignancy-associated renal disease 

Malignancy-associated renal disease
Malignancy-associated renal disease

A. Neil Turner

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 25 February 2021

Malignancies can affect the kidneys by direct invasion, metabolic and remote effects of tumour products, deposition of tumour products, triggering of immune reactions, and effects of treatment.

Particular malignancy-associated renal diseases include the following:

Thrombotic microangiopathy—particularly reported for malignancies of the stomach, pancreas, and prostate, and also with certain chemotherapeutic agents.

Minimal-change nephrotic syndrome—rarely caused by lymphoma.

Membranous nephropathy—associated with malignancy, usually of solid organs, in 5 to 11% of cases. Malignant disease is typically advanced and obvious when nephrotic syndrome or heavy proteinuria is recognized. Very few treatable and otherwise subclinical tumours are uncovered by investigation in routine clinical practice.

Focal necrotizing and crescentic nephritis—may rarely be associated with malignancy, when they are usually antineutrophil cytoplasmic antibody negative.

Proteinuria—may be caused by agents that modulate interferons or vascular endothelial growth factors.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.